Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2015 | Nov. 10, 2015 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Sep. 30, 2015 | |
Document Fiscal Year Focus | 2,015 | |
Document Fiscal Period Focus | Q3 | |
Trading Symbol | OXGN | |
Entity Registrant Name | OXIGENE INC | |
Entity Central Index Key | 908,259 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 26,544,934 |
Condensed Balance Sheets
Condensed Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 |
Current assets: | ||
Cash | $ 30,251 | $ 30,031 |
Prepaid expenses and other current assets | 416 | 322 |
Total current assets | 30,667 | 30,353 |
Property and equipment, net of accumulated depreciation of $233 and $242 at September 30, 2015 and December 31, 2014, respectively | 36 | 37 |
Other assets | 33 | 33 |
Total assets | 30,736 | 30,423 |
Current liabilities: | ||
Accounts payable | 317 | 335 |
Accrued compensation and benefits | 733 | 841 |
Accrued research and development | 479 | 36 |
Accrued other | 169 | 207 |
Total current liabilities | $ 1,698 | $ 1,419 |
Commitments and contingencies | ||
Stockholders' equity | ||
Preferred stock, $ 0.01 par value, 15,000 shares authorized; No shares issued and outstanding | ||
Common stock, $ 0.01 par value, 70,000 shares authorized; 26,545 and 20,705 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively | $ 265 | $ 207 |
Additional paid-in capital | 289,616 | 279,952 |
Accumulated deficit | (260,843) | (251,155) |
Total stockholders' equity | 29,038 | 29,004 |
Total liabilities and stockholders' equity | $ 30,736 | $ 30,423 |
Condensed Balance Sheets (Paren
Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 |
Statement of Financial Position [Abstract] | ||
Accumulated depreciation | $ 233 | $ 242 |
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 15,000,000 | 15,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 70,000,000 | 70,000,000 |
Common stock, shares issued | 26,545,000 | 20,705,000 |
Common stock, shares outstanding | 26,545,000 | 20,705,000 |
Condensed Statements of Compreh
Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Operating expenses: | ||||
Research and development | $ 2,457 | $ 2,240 | $ 6,107 | $ 5,798 |
General and administrative | 1,142 | 1,213 | 3,597 | 4,207 |
Total operating expenses | 3,599 | 3,453 | 9,704 | 10,005 |
Loss from operations | (3,599) | (3,453) | (9,704) | (10,005) |
Investment income | 7 | 2 | 15 | 4 |
Other income (expense), net | 1 | 1 | (8) | |
Net loss and comprehensive loss | $ (3,592) | $ (3,450) | $ (9,688) | $ (10,009) |
Basic and diluted net loss per share attributable to common stock | $ (0.14) | $ (0.17) | $ (0.39) | $ (0.64) |
Weighted-average number of common shares outstanding | 26,545 | 20,705 | 24,748 | 15,716 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2015 | Sep. 30, 2014 | |
Operating activities: | ||
Net loss | $ (9,688) | $ (10,009) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 15 | 12 |
Amortization of license agreement | 70 | |
Stock-based compensation | 527 | 352 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | (94) | (153) |
Accounts payable and accrued expenses | 279 | 423 |
Net cash used in operating activities | (8,961) | (9,305) |
Investing activities: | ||
Purchases of furniture, fixtures, equipment and other assets | (14) | (6) |
Net cash used in investing activities | (14) | (6) |
Financing activities: | ||
Proceeds from issuance of common stock, net of issuance costs | 9,195 | 25,681 |
Proceeds from exercise of warrants into common stock, net of issuance costs | 9,512 | |
Net cash provided by financing activities | 9,195 | 35,193 |
Increase in cash | 220 | 25,882 |
Cash at beginning of period | 30,031 | 7,005 |
Cash at end of period | $ 30,251 | $ 32,887 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2015 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 1. Summary of Significant Accounting Policies Description of Business OXiGENE, Inc. (“OXiGENE” or the “Company”) is incorporated in the state of Delaware and is a clinical-stage biopharmaceutical company developing vascular disrupting agents (“VDAs”) to treat cancer. VDAs selectively disrupt abnormal blood vessels that sustain tumors. The Company has two VDA drug candidates currently being tested in clinical trials, CA4P (combretastatin A4 phosphate, or fosbretabulin) and OXi4503. The Company is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients. The Company is subject to a number of risks similar to other biopharmaceutical companies that do not have approval for their product candidates, including the need to obtain adequate additional funding, possible failure of clinical trials, the need to obtain marketing approval for the Company’s investigational drugs, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates should they be approved for marketing, and protection of its proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. OXiGENE expects to incur additional operating losses over the next several years as it develops its product candidates, and will need additional capital for this development. Additional funding may not be available on acceptable terms, or at all, and if funding is not available, the Company may need to scale back or abandon its product candidates. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The financial statements do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, however, all adjustments (consisting primarily of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2015. The balance sheet at December 31, 2014 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. For further information, refer to the financial statements and footnotes thereto included in the Annual Report on Form 10-K for the Company for the year ended December 31, 2014. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. |
Stockholders' Equity
Stockholders' Equity | 9 Months Ended |
Sep. 30, 2015 | |
Equity [Abstract] | |
Stockholders' Equity | 2. Stockholders’ Equity March 2015 Financing On March 25, 2015, the Company completed a financing with institutional investors in which it raised $10.0 million, or approximately $9.2 million after deducting placement agents’ fees and other offering expenses. Investors purchased shares of the Company’s common stock at a price of $1.7125 per share and received one warrant to purchase one half of a share of the Company’s common stock at the same exercise price per share as each share of common stock purchased. A total of 5,839,420 shares of common stock and warrants for the purchase of 2,919,710 shares of common stock were issued. The warrants were exercisable immediately after issuance and expire 5 years from the date of issuance. Also, in connection with the financing, the Company issued to its placement agent and related persons warrants to purchase 233,577 shares of the Company’s common stock, which were exercisable immediately after issuance, have an exercise price of $2.13 per share and expire on March 20, 2020. Warrants The following is a summary of the Company’s outstanding common stock warrants as of September 30, 2015 and December 31, 2014: Number of warrants outstanding Warrants Issued in Connection with: Expiration Date Exercise September 30, December 31, Private Placement Series A 04/16/18 $ 3.40 1,460 1,460 Private Placement Series B 04/16/15 $ 3.40 — 757 2013 Private Placement 09/23/18 $ 2.80 147 147 2014 Public Offering 02/18/19 $ 2.75 1,872 1,872 2014 Public Offering 02/11/19 $ 2.56 293 293 2014 Private Placement 08/28/19 $ 2.90 2,700 2,700 2014 Private Placement 06/14/17 $ 3.70 216 216 2015 Private Placement 03/25/20 $ 1.71 2,920 — 2015 Private Placement 03/20/20 $ 2.13 234 — Total Warrants Outstanding 9,842 7,445 Options and restricted stock At the Company’s 2015 annual meeting, stockholders approved the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). Under the 2015 Plan, up to 4,000,000 shares of the Company’s common stock may be issued pursuant to awards granted in the form of incentive stock options, nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards to employees, consultants, and directors. The 2015 Plan also allows additional shares of the Company’s common stock to be issued if awards outstanding under the Company’s 2005 Stock Plan (the “2005 Plan”) are cancelled, forfeited, surrendered, or terminated after the April 25, 2015 expiration of the 2005 Plan, provided that no more than 725,781 shares of the Company’s common stock shall be added to the 2015 Plan from the 2005 Plan. The following is a summary of the Company’s stock option activity under the 2005 and 2015 Plans for the nine months ended September 30, 2015: Options Grant Options Weighted Weighted Aggregate (In thousands) (Years) (In thousands) Balance at December 31, 2014 54 672 $ 3.63 8.49 Options granted (1,792 ) 1,792 $ 1.41 Options forfeited 272 (272 ) $ 2.03 Options expired — — $ — Options authorized 4,000 — $ — Balance at September 30, 2015 2,534 2,192 $ 2.01 8.73 $ — Exercisable at September 30, 2015 450 $ 3.51 7.68 $ — Vested and expected to vest at September 30, 2015 1,517 $ 2.22 8.45 $ — As of September 30, 2015, there was approximately $1.2 million of unrecognized compensation cost related to stock option awards that is expected to be recognized as expense over a weighted average period of approximately 2.9 years. The fair values for the stock options granted in the nine-month period ended September 30, 2015 were estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions: Weighted Average Assumptions Nine months ended September 30, 2015 2014 Risk-free interest rate 1.71 % 1.57 % Expected life (years) 6 4 Expected volatility 92 % 101 % Dividend yield 0.00 % 0.00 % Options issued during the nine month period ended September 30, 2015 generally vest over a three or four year period from the date of grant, except for options to purchase 75,000 shares of common stock which will only vest upon a change of control of the Company if certain other conditions are also met. |
Net Loss Per Share
Net Loss Per Share | 9 Months Ended |
Sep. 30, 2015 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | 3. Net Loss Per Share Basic and diluted net loss per share was calculated by dividing the net loss per share attributed to the Company’s common shares by the weighted-average number of common shares outstanding during the period. Diluted net loss per share includes the effect of all dilutive, potentially issuable common equivalent shares as defined using the treasury stock method. All of the Company’s common stock equivalents are anti-dilutive due to the Company’s net loss position for all periods presented. Accordingly, common stock equivalents of approximately 2,192,000 stock options and 9,842,000 warrants at September 30, 2015 and 642,000 stock options and 7,445,000 warrants at September 30, 2014, were excluded from the calculation of weighted average shares for diluted net loss per share. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 4. Commitments and Contingencies Clinical Research Organization and Manufacturing Commitments As of September 30, 2015, the Company has a balance of unapplied purchase orders for expenditures related to external clinical research and outsourced drug manufacturing of approximately $4.6 million, of which the Company expects to incur approximately $1.7 million over the next three months. |
Summary of Significant Accoun10
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2015 | |
Accounting Policies [Abstract] | |
Description of Business | Description of Business OXiGENE, Inc. (“OXiGENE” or the “Company”) is incorporated in the state of Delaware and is a clinical-stage biopharmaceutical company developing vascular disrupting agents (“VDAs”) to treat cancer. VDAs selectively disrupt abnormal blood vessels that sustain tumors. The Company has two VDA drug candidates currently being tested in clinical trials, CA4P (combretastatin A4 phosphate, or fosbretabulin) and OXi4503. The Company is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients. The Company is subject to a number of risks similar to other biopharmaceutical companies that do not have approval for their product candidates, including the need to obtain adequate additional funding, possible failure of clinical trials, the need to obtain marketing approval for the Company’s investigational drugs, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates should they be approved for marketing, and protection of its proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. OXiGENE expects to incur additional operating losses over the next several years as it develops its product candidates, and will need additional capital for this development. Additional funding may not be available on acceptable terms, or at all, and if funding is not available, the Company may need to scale back or abandon its product candidates. |
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The financial statements do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, however, all adjustments (consisting primarily of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2015. The balance sheet at December 31, 2014 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. For further information, refer to the financial statements and footnotes thereto included in the Annual Report on Form 10-K for the Company for the year ended December 31, 2014. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Equity [Abstract] | |
Summary of the Company's Outstanding Common Stock Warrants | The following is a summary of the Company’s outstanding common stock warrants as of September 30, 2015 and December 31, 2014: Number of warrants outstanding Warrants Issued in Connection with: Expiration Date Exercise September 30, December 31, Private Placement Series A 04/16/18 $ 3.40 1,460 1,460 Private Placement Series B 04/16/15 $ 3.40 — 757 2013 Private Placement 09/23/18 $ 2.80 147 147 2014 Public Offering 02/18/19 $ 2.75 1,872 1,872 2014 Public Offering 02/11/19 $ 2.56 293 293 2014 Private Placement 08/28/19 $ 2.90 2,700 2,700 2014 Private Placement 06/14/17 $ 3.70 216 216 2015 Private Placement 03/25/20 $ 1.71 2,920 — 2015 Private Placement 03/20/20 $ 2.13 234 — Total Warrants Outstanding 9,842 7,445 |
Summary of the Company's Stock Option Activity under the 2005 and 2015 Plans | The following is a summary of the Company’s stock option activity under the 2005 and 2015 Plans for the nine months ended September 30, 2015: Options Grant Options Weighted Weighted Aggregate (In thousands) (Years) (In thousands) Balance at December 31, 2014 54 672 $ 3.63 8.49 Options granted (1,792 ) 1,792 $ 1.41 Options forfeited 272 (272 ) $ 2.03 Options expired — — $ — Options authorized 4,000 — $ — Balance at September 30, 2015 2,534 2,192 $ 2.01 8.73 $ — Exercisable at September 30, 2015 450 $ 3.51 7.68 $ — Vested and expected to vest at September 30, 2015 1,517 $ 2.22 8.45 $ — |
Weighted-Average Assumptions | The fair values for the stock options granted in the nine-month period ended September 30, 2015 were estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions: Weighted Average Assumptions Nine months ended September 30, 2015 2014 Risk-free interest rate 1.71 % 1.57 % Expected life (years) 6 4 Expected volatility 92 % 101 % Dividend yield 0.00 % 0.00 % |
Summary of Significant Accoun12
Summary of Significant Accounting Policies - Additional Information (Detail) | 9 Months Ended |
Sep. 30, 2015Candidate | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Number of VDA drug candidates tested | 2 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions | Mar. 25, 2015 | Sep. 30, 2015 |
Stockholders Equity [Line Items] | ||
Gross proceeds from issuance of common stock and warrants | $ 10 | |
Net proceeds from issuance of common stock and warrants | $ 9.2 | |
Term of warrants | 5 years | |
Number of shares authorized for grant | 4,000,000 | |
Weighted average period for recognizing unrecognized compensation cost as expense | 2 years 10 months 24 days | |
Unrecognized compensation cost related to stock option awards | $ 1.2 | |
Number of options granted | 75,000 | |
March 2015 Financing [Member] | ||
Stockholders Equity [Line Items] | ||
Share price of common stock and warrants issued | $ 1.7125 | |
Number of warrants issued for each unit issued | 0.5 | |
Common stock issued during period | 5,839,420 | |
Warrants exercised | 2,919,710 | |
2015 Equity Incentive Plan [Member] | ||
Stockholders Equity [Line Items] | ||
Number of shares authorized for grant | 4,000,000 | |
Number of additional shares authorized for grant | 725,781 | |
Stock option plan expiration date | Apr. 25, 2015 | |
Private Placement [Member] | ||
Stockholders Equity [Line Items] | ||
Exercise Price | $ 2.13 | |
Warrant expiration date | Mar. 20, 2020 | |
Private Placement [Member] | March 2015 Financing [Member] | ||
Stockholders Equity [Line Items] | ||
Warrants exercised | 233,577 | |
Minimum [Member] | ||
Stockholders Equity [Line Items] | ||
Option vesting period | 3 years | |
Maximum [Member] | ||
Stockholders Equity [Line Items] | ||
Option vesting period | 4 years |
Stockholders' Equity - Summary
Stockholders' Equity - Summary of Company's Outstanding Common Stock Warrants (Detail) - $ / shares shares in Thousands | 9 Months Ended | |
Sep. 30, 2015 | Dec. 31, 2014 | |
Class of Warrant or Right [Line Items] | ||
Number of warrants outstanding | 9,842 | 7,445 |
Private Placement Series A [Member] | ||
Class of Warrant or Right [Line Items] | ||
Expiration Date | Apr. 16, 2018 | |
Exercise Price | $ 3.40 | |
Number of warrants outstanding | 1,460 | 1,460 |
Private Placement Series B [Member] | ||
Class of Warrant or Right [Line Items] | ||
Expiration Date | Apr. 16, 2015 | |
Exercise Price | $ 3.40 | |
Number of warrants outstanding | 757 | |
2013 Private Placement [Member] | ||
Class of Warrant or Right [Line Items] | ||
Expiration Date | Sep. 23, 2018 | |
Exercise Price | $ 2.80 | |
Number of warrants outstanding | 147 | 147 |
2014 Public Offering [Member] | ||
Class of Warrant or Right [Line Items] | ||
Expiration Date | Feb. 18, 2019 | |
Exercise Price | $ 2.75 | |
Number of warrants outstanding | 1,872 | 1,872 |
2014 Public Offering [Member] | ||
Class of Warrant or Right [Line Items] | ||
Expiration Date | Feb. 11, 2019 | |
Exercise Price | $ 2.56 | |
Number of warrants outstanding | 293 | 293 |
2014 Private Placement [Member] | ||
Class of Warrant or Right [Line Items] | ||
Expiration Date | Aug. 28, 2019 | |
Exercise Price | $ 2.90 | |
Number of warrants outstanding | 2,700 | 2,700 |
2014 Private Placement [Member] | ||
Class of Warrant or Right [Line Items] | ||
Expiration Date | Jun. 14, 2017 | |
Exercise Price | $ 3.70 | |
Number of warrants outstanding | 216 | 216 |
2015 Private Placement [Member] | ||
Class of Warrant or Right [Line Items] | ||
Expiration Date | Mar. 25, 2020 | |
Exercise Price | $ 1.71 | |
Number of warrants outstanding | 2,920 | |
2015 Private Placement [Member] | ||
Class of Warrant or Right [Line Items] | ||
Expiration Date | Mar. 20, 2020 | |
Exercise Price | $ 2.13 | |
Number of warrants outstanding | 234 |
Stockholders' Equity - Summar15
Stockholders' Equity - Summary of the Company's Stock Option Activity under the 2005 and 2015 Plans (Detail) $ / shares in Units, $ in Thousands | 9 Months Ended |
Sep. 30, 2015USD ($)$ / sharesshares | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Options Available for Grant, Beginning Balance | 54,000 |
Options Available for Grant, Options granted | (1,792,000) |
Options Available for Grant, Options forfeited | 272,000 |
Options Available for Grant, Options expired | 0 |
Options Available for Grant, Options authorized | 4,000,000 |
Options Available for Grant, Ending Balance | 2,534,000 |
Options Outstanding, Beginning Balance | 672,000 |
Options Outstanding, Options granted | 1,792,000 |
Options Outstanding, Options forfeited | (272,000) |
Options Outstanding, Options expired | 0 |
Options Outstanding, Ending Balance | 2,192,000 |
Options Outstanding, Exercisable, Ending Balance | 450,000 |
Options Outstanding, Vested and expected to vest, Ending Balance | 1,517,000 |
Weighted Average Exercise Price, Beginning Balance | $ / shares | $ 3.63 |
Weighted Average Exercise Price, Options granted | $ / shares | 1.41 |
Weighted Average Exercise Price, Options forfeited | $ / shares | 2.03 |
Weighted Average Exercise Price, Options expired | $ / shares | 0 |
Weighted Average Exercise Price, Ending Balance | $ / shares | 2.01 |
Weighted Average Exercise Price, Exercisable, Ending Balance | $ / shares | 3.51 |
Weighted Average Exercise Price, Vested and expected to vest, Ending Balance | $ / shares | $ 2.22 |
Weighted Average Remaining Contractual Life, Beginning Balance | 8 years 5 months 27 days |
Weighted Average Remaining Contractual Life, Ending Balance | 8 years 8 months 23 days |
Weighted Average Remaining Contractual Life, Exercisable, Ending Balance | 7 years 8 months 5 days |
Weighted Average Remaining Contractual Life, Vested and expected to vest, Ending Balance | 8 years 5 months 12 days |
Aggregate Intrinsic Value, Ending Balance | $ | $ 0 |
Aggregate Intrinsic Value, Exercisable, Ending Balance | $ | 0 |
Aggregate Intrinsic Value, Vested and expected to vest, Ending Balance | $ | $ 0 |
Stockholders' Equity - Weighted
Stockholders' Equity - Weighted-Average Assumptions (Detail) | 9 Months Ended | |
Sep. 30, 2015 | Sep. 30, 2014 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||
Risk-free interest rate | 1.71% | 1.57% |
Expected life (years) | 6 years | 4 years |
Expected volatility | 92.00% | 101.00% |
Dividend yield | 0.00% | 0.00% |
Net Loss Per Share - Additional
Net Loss Per Share - Additional Information (Detail) - shares | 9 Months Ended | |
Sep. 30, 2015 | Sep. 30, 2014 | |
Stock Options [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock excluded from the calculation of weighted average shares for diluted net loss per share | 2,192,000 | 642,000 |
Warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock excluded from the calculation of weighted average shares for diluted net loss per share | 9,842,000 | 7,445,000 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) $ in Millions | Sep. 30, 2015USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
Unapplied purchase commitment due | $ 4.6 |
Unapplied purchase commitment due over the next six months | $ 1.7 |